Hansjakob Furrer

Hansjakob Furrer

Auto-generated profile, based on publicly available information

Hansjakob Furrer

Department of Infectious Diseases, Bern University Hospital, University of Bern

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Annals of Internal Medicine
Verified
Journal Article
Closed access
BSBernard Surial
Bernard Surial
CMCatrina Mugglin
Catrina Mugglin
ACAlexandra Calmy
Alexandra Calmy
MCMatthias Cavassini
Matthias Cavassini
HGHuldrych Günthard
Huldrych Günthard
ARAndri Rauch
Andri Rauch
This study compared changes in body weight, lipid levels, and development of obesity over 18 months among patients with HIV who switched from tenofovir disoproxil fumarate to tenofovir alafenamide ... Visual Metabolic Changes After Replacing TDF With TAF. This study compared changes in body weight, lipid levels, and development of obesity over 18 months among patients with HIV who switc... Background: Tenofovir-based antiretroviral therapy (ART) has become first-line in all major HIV treatment guidelines. Compared with tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF) ...

1 June 2000 in The Lancet
Verified
Journal Article
Closed access
HFHansjakob Furrer
Hansjakob Furrer
MOMilos Opravil
Milos Opravil
EBEnos Bernasconi
Enos Bernasconi
Amalio TelentiAmalio Telenti
Amalio Telenti
MEMatthias Egger
Matthias Egger

12 January 2024 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
MWM S R Weber
M S R Weber
JRJ J Duran Ramirez
J J Duran Ramirez
MHMaxime Hentzien
Maxime Hentzien
MCMatthias Cavassini
Matthias Cavassini
EBEnos Bernasconi
Enos Bernasconi
KKK Kusejko
K Kusejko
Background: Advancements in access to antiretroviral therapy (ART) and human immunodeficiency virus (HIV) care have led to a decline in AIDS-related deaths among people with HIV (PWH) in Switzerland. However, data on the ongoing changes in causes of death among PWH over the past 15 years are scarce. Methods: We investigated all reported deaths in the Swiss HIV Cohort Study between 2005 and 2022. Causes of death were categorized using the Coding Causes of Death in HIV protocol. The statistical analysis included demographic stratification to identify time trends and logistic regression models to determine associated factors for the underlying cause of death. Results: In total, 1630 deaths were reported, with 23.7% of individuals assigned female sex at birth. These deaths included 147 (9.0%) HIV/AIDS-related deaths, 373 (22.9%) due to non-AIDS, non-hepatic cancers, 166 (10.2%) liver-related deaths, and 158 (9.7%) cardiovascular-related deaths. The median age at death (interquartile range) increased from 45.0 (40.0–53.0) years in 2005–2007 to 61.0 (56.0–69.5) years in 2020–2022. HIV/AIDS- and liver-related deaths decreased, whereas deaths from non-AIDS, non-hepatic cancers increased and cardiovascular-related deaths remained relatively stable. Conclusions: The proportionally decreasing HIV/AIDS and liver-related deaths showcase the effectiveness of ART, comprehensive HIV patient care, and interventions targeting hepatitis C virus coinfection. Future research should focus on managing cancer and cardiovascular-related conditions as the new leading causes of death among PWH. Comprehensive healthcare strategies focusing on non–AIDS-related comorbid conditions, cancer management, and sustaining liver and cardiovascular health are needed to bridge the ongoing health disparities between PWH and the general population.

1 August 2016 in Genetics in Medicine
Verified
Journal Article
Open access
PMPaul J McLaren
Paul J McLaren
JRJean Louis Raisaro
Jean Louis Raisaro
MAManel Aouri
Manel Aouri
MRMargalida Rotger
Margalida Rotger
EAErman Ayday
Erman Ayday
Amalio TelentiAmalio Telenti
Amalio Telenti
The implementation of genomic-based medicine is hindered by unresolved questions regarding data privacy and delivery of interpreted results to health-care practitioners. We used DNA-based prediction of HIV-related outcomes as a model to explore critical issues in clinical genomics. We genotyped 4,149 markers in HIV-positive individuals. Variants allowed for prediction of 17 traits relevant to HIV medical care, inference of patient ancestry, and imputation of human leukocyte antigen (HLA) types. Genetic data were processed under a privacy-preserving framework using homomorphic encryption, and clinical reports describing potentially actionable results were delivered to health-care providers. A total of 230 patients were included in the study. We demonstrated the feasibility of encrypting a large number of genetic markers, inferring patient ancestry, computing monogenic and polygenic trait risks, and reporting results under privacy-preserving conditions. The average execution time of a multimarker test on encrypted data was 865 ms on a standard computer. The proportion of tests returning potentially actionable genetic results ranged from 0 to 54%. The model of implementation presented herein informs on strategies to deliver genomic test results for clinical care. Data encryption to ensure privacy helps to build patient trust, a key requirement on the road to genomic-based medicine.Genet Med 18 8, 814-822.

1 January 2013 in The Scientific World Journal
Verified
Journal Article
Open access
PDF file
CPCarmen A Pfortmueller
Carmen A Pfortmueller
AEAnastasios Efeoglou
Anastasios Efeoglou
HFHansjakob Furrer
Hansjakob Furrer
AEAristomenis K Exadaktylos
Aristomenis K Exadaktylos
Dog bites in humans are a complex problem, embracing both public health and animal welfare. The primary aim of this study is to examine primary and secondary presentations related to dog bite injuries in adults. Methods. We retrospectively assessed all adult patients admitted with a dog bite injury to the Emergency Department of Bern University Hospital. Results. A total of 431 patients were eligible for the study. Forty‐nine (11.4%) of all patients were admitted with secondary presentations. Bites to the hands were most common (177, 41.1%). All patients (47, 100%) with secondary presentations were admitted because of signs of infection. The median time since the dog bite was 3.8 days (SD 3.9, range 1–21). Thirty‐one patients had already been treated with antibiotic; coamoxicillin was the most common primary antibiotic therapy (27/47 patients, 57.4%). Patients with injuries to the hand were at increased risk of secondary presentations (OR 2.08, 95% CI 1.21–3.55, P < 0.006). Conclusion. Dog bite injuries to the hands are a major problem. They often lead to infectious complications. Immediate antibiotic therapy should carefully be evaluated for each patient.

1 April 2012 in Clinical Nephrology
Verified
Journal Article
Closed access
SVSaskia M.E. Vrouenraets
Saskia M.E. Vrouenraets
CFChristoph A. Fux
Christoph A. Fux
FWFerdinand W.N.M. Wit
Ferdinand W.N.M. Wit
EGEvian Fernandez Garcia
Evian Fernandez Garcia
KBKees Brinkman
Kees Brinkman
PGPeter Peter Reiss for the PREPARE Study Group
Peter Peter Reiss for the PREPARE Study Group
Monitoring of renal function becomes increasingly important in the aging population of HIV-1 infected patients. We compared Cockroft & Gault (C&G), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Modification of Diet in Renal Disease (MDRD), Cystatin C- and 24 h urine-based estimated GFR (eGFR) with the gold standard, measured GFR (mGFR) using [125I]-iothalamate